Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Mark Fallick"'
1
Akademický článek
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
Autor: Lindsey Gallagher, Jerry Xiao, Jessica Hsueh, Sarthak Shah, Malika Danner, Alan Zwart, Marilyn Ayoob, Thomas Yung, Tiffany Simpson, Mark Fallick, Deepak Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Sean P. Collins
Publikováno v: Frontiers in Oncology, Vol 13 (2023)
IntroductionInjectable GnRH receptor agonists have been shown to improve cancer control when combined with radiotherapy. Prostate SBRT offers an abbreviated treatment course with comparable efficacy to conventionally fractionated radiotherapy. Relugo
Externí odkaz: https://doaj.org/article/9f81875151af45b5a8e57fa86e678535
Zobrazit plný text záznamu
6
Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database
Autor: Rana R. McKay, Raj Gandhi, Eric Yang, Janis Pruett, Esmond Nwokeji, Mark Fallick
Publikováno v: Journal of Clinical Oncology. 41:74-74
74 Background: Relugolix, an oral gonadotropin releasing hormone (GnRH) receptor antagonist, was FDA approved for the treatment of adults with advanced prostate cancer (PC) in December 2020 and became commercially available in January 2021. Data from
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b9873d692b3dad294ac6f1a737f2031a
https://doi.org/10.1200/jco.2023.41.6_suppl.74
Zobrazit plný text záznamu
7
A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX
Autor: Daniel Eidelberg Spratt, Rana R. McKay, Tanya B. Dorff, Benjamin H Lowentritt, Mark Fallick, Sarah Hanson, Ashley Ross
Publikováno v: Journal of Clinical Oncology. 41:TPS398-TPS398
TPS398 Background: Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) receptor agonists or antagonists are the foundation of advanced prostate cancer (aPC) treatment. Relugolix is an oral non-peptide GnRH receptor antagonis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52701d593f69a736e738969290b7952b
https://doi.org/10.1200/jco.2023.41.6_suppl.tps398
Zobrazit plný text záznamu
8
Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU)
Autor: Fred Saad, Daniel J. George, Michael Cookson, Daniel Saltzstein, Ronald F. Tutrone, Marc B. Garnick, Bruce Brown, Sophia Lu, Mark Fallick, Sarah Hanson, E. David Crawford, Neal D. Shore
Publikováno v: Journal of Clinical Oncology. 40:5073-5073
5073 Background: BMI has been correlated with adverse prostate cancer outcomes, such as risk of biochemical failure, mortality and androgen deprivation therapy complications. Relugolix is a FDA-approved, once-daily oral GnRH receptor antagonist that
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d58f3077ab84a7c48911c7035fba86d2
https://doi.org/10.1200/jco.2022.40.16_suppl.5073
Zobrazit plný text záznamu
9
Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide
Autor: Daniel J. George, Fred Saad, Christopher Michael Pieczonka, Michael Cookson, Daniel Saltzstein, Ronald F. Tutrone, Bruce Brown, Sophia Lu, Mark Fallick, Sarah Hanson, Neal D. Shore
Publikováno v: Journal of Clinical Oncology. 40:105-105
105 Background: Prostate cancer disproportionately impacts Black men, with a higher incidence and worse outcomes relative to other races (Siegel DA, MMWR Morb Mortal Wkly Rep. 2020;69:1473). In the international phase 3 HERO study, relugolix, the onc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2e32ee24c96b4b7ecd3772428dc3966c
https://doi.org/10.1200/jco.2022.40.6_suppl.105
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje